Cytori (CYTX) Announces Celution One System is Granted European CE Mark Approval
Tweet
Share
E-mailGet Alerts CYTX Hot Sheet
Join SI Premium – FREE
Cytori's (NASDAQ: CYTX) Celution One System, the next-generation device of the Company's Celution platform, has been granted CE Mark approval. Celution One is tailored specifically for the hospital as a platform device with potential life-critical applications across multiple specialties. The Celution platform is a GMP-compliant technology that extracts and concentrates a patient's own stem and progenitor cells from adipose (fat) at the point-of-care.
The Celution One is intended for hospital-based use with key improvements including greater cell yield, greater range of processing volumes and faster processing times, increasing the versatility and efficiencies of potential treatments. Additionally, it contains new features for improved operator ease-of-use
The Celution One is intended for hospital-based use with key improvements including greater cell yield, greater range of processing volumes and faster processing times, increasing the versatility and efficiencies of potential treatments. Additionally, it contains new features for improved operator ease-of-use
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nu Skin EVP of global sales takes medical leave
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
